Impact of immunocompromised status on real-world outcomes with avelumab treatment in advanced Merkel cell carcinoma: findings from the prospective MCC-TRIM registry

Clicks: 11
ID: 332011
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #401 of 412 articles by views in the british journal of dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 412 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
This study observed the real-world outcomes with avelumab treatment in patients with Merkel cell carcinoma in Germany by immunocompromised status. Objective response rates with first-line avelumab were similar in immunocompromised and immunocompetent patients, however, long-term survival was shorter in the immunocompromised subgroup. Rates of avelumab-related adverse drug reactions were comparable between the subgroups. These findings demonstrate the clinical activity and safety of avelumab in both immunocompetent and immunocompromised patients with Merkel cell carcinoma.
Reference Key
openalex_W7221339212 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jürgen Christian Becker, Seyed Hamidreza Mahmoudpour, Dirk Schadendorf, Ulrike Leiter, Friedegund Meier, Rudolf Alexander Herbst, Stephan Grabbe, Christoffer Gebhardt, Fabian Ziller, Claudia Pföhler, Peter Mohr, Lisa Zimmer, Emmanuelle Boutmy, Dina Oksen, Mairead Kearney, Katia Ruth, Sebastian Hoff, Margarita Shlaen, Selma Ugurel
Are you one of these authors? Claim your profile
Journal the british journal of dermatology
Year 2026
DOI
10.1093/bjd/ljag445
URL
https://doi.org/10.1093/bjd/ljag445
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.